About Us

We are a leading T cell receptor (TCR) biotechnology company, focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.

Our most advanced therapeutic programmes are focused on oncology, and we also have programmes in infectious and autoimmune diseases. We have a pipeline of proprietary and partnered programmes in development and our lead programme, tebentafusp (IMCgp100), which has been granted Fast Track Designation by the US Food & Drug Administration, is in pivotal clinical studies as a treatment for patients with metastatic uveal melanoma.

Our partners include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly, and the Bill and Melinda Gates Foundation.

Our story

1999

Dr Bent Jakobsen founded Avidex as a spin-off company from his research into T cell receptors at the University of Oxford.

2006

Avidex is acquired by Medigene AG.

2008

With the help of private investment, the technology is brought back in-house and two sister companies are founded; Immunocore focusing on soluble TCR technology and Adaptimmune focusing on cellular TCR therapy.

2010

Immunocore launches its first clinical trial for IMCgp100 in malignant melanoma.

2013

Immunocore establishes partnerships with GSK, Genentech & MedImmune to discover and develop novel cancer targets.

2013

Immunocore initiates a Phase II clinical trial for IMCgp100 in melanoma.

2014

Immunocore partners with Eli Lilly to research, co-discover and co-develop novel therapies.

2015

Immunocore secures $320 m investment in Europe's largest private life sciences financing round.

2015

Immunocore wins 'Biotech of the Year' at the SCRIP awards.

2015

Immunocore opens up its US office in Philadelphia.

2015

IMCgp100 is accepted for the EMA's adaptive pathway pilot programme for treatment of metastatic uveal melanoma, a rare and fatal disease with few treatment options.

2016

IMCgp100, Durvalumab and Tremelimumab combination trial is initiated with MedImmune for treatment of metastatic cutaneous melanoma.

2016

IMCgp100 is granted Orphan Drug Designation by the FDA for the treatment of uveal melanoma.

2017

Immunocore announces significant laboratory expansion at Milton Park, Oxfordshire.

2017

Immunocore announces a collaboration and $40m investment from the Bill and Melinda Gates Foundation to accelerate the development of ImmTAV® and ImmTAB® technology for the treatment of infectious diseases.

2018

Immunocore’s second ImmTAC molecule, IMCnyeso, enters Phase I clinical trials for treatment of melanoma, synovial sarcoma, urothelial carcinoma and non-small cell lung cancer (NSCLC).

2018

Partnership with Genentech to expand existing discovery collaboration to co-develop Immunocore’s therapeutic candidate IMC-C103C.

1999

Dr Bent Jakobsen founded Avidex as a spin-off company from his research into T cell receptors at the University of Oxford.

2006

Avidex is acquired by Medigene AG.

2008

With the help of private investment, the technology is brought back in-house and two sister companies are founded; Immunocore focusing on soluble TCR technology and Adaptimmune focusing on cellular TCR therapy.

2010

Immunocore launches its first clinical trial for IMCgp100 in malignant melanoma.

2013

Immunocore establishes partnerships with GSK, Genentech & MedImmune to discover and develop novel cancer targets.

2013

Immunocore initiates a Phase II clinical trial for IMCgp100 in melanoma.

2014

Immunocore partners with Eli Lilly to research, co-discover and co-develop novel therapies.

2015

Immunocore secures $320 m investment in Europe's largest private life sciences financing round.

2015

Immunocore wins 'Biotech of the Year' at the SCRIP awards.

2015

Immunocore opens up its US office in Philadelphia.

2015

IMCgp100 is accepted for the EMA's adaptive pathway pilot programme for treatment of metastatic uveal melanoma, a rare and fatal disease with few treatment options.

2016

IMCgp100, Durvalumab and Tremelimumab combination trial is initiated with MedImmune for treatment of metastatic cutaneous melanoma.

2016

IMCgp100 is granted Orphan Drug Designation by the FDA for the treatment of uveal melanoma.

2017

Immunocore announces significant laboratory expansion at Milton Park, Oxfordshire.

2017

Immunocore announces a collaboration and $40m investment from the Bill and Melinda Gates Foundation to accelerate the development of ImmTAV® and ImmTAB® technology for the treatment of infectious diseases.

2018

Immunocore’s second ImmTAC molecule, IMCnyeso, enters Phase I clinical trials for treatment of melanoma, synovial sarcoma, urothelial carcinoma and non-small cell lung cancer (NSCLC).

2018

Partnership with Genentech to expand existing discovery collaboration to co-develop Immunocore’s therapeutic candidate IMC-C103C.

Our vision

Our vision at Immunocore is to transform patients’ lives with our distinctive T cell receptor technology. We have a well-established pipeline of both wholly-owned and partnered programmes focused on the discovery and development of ImmTAC® molecules to treat a broad spectrum of cancers, infectious diseases and autoimmune diseases. 

Our vision is steered by our five guiding principles:

value_icon_torch.svg

Lead with purpose

Everything we do stems from our common goal to help people affected by challenging diseases.

value_icon_ear.svg

Listen to everyone

We’re open, honest and ready to share and learn from each other.

value_icon_multi_arrows.svg

Challenge the status quo

We’re constantly curious and believe we can always learn and improve.

value_icon_chain.svg

Trust in each other

We work together, collaboratively and with mutual respect towards our purpose.

value_icon_shutes.svg

Never give up hope

We’re passionately hopeful about the possibilities before us.

Management team

avatar_180x180_Bahija_Jallal.jpg

Dr Bahija Jallal

Chief Executive Officer

avatar_180x180_Bahija_Jallal.jpg

Dr Bahija Jallal

Chief Executive Officer

Dr. Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore. Prior to joining Immunocore in January 2019, she was President of MedImmune, Astra Zeneca’s global biologics research and development unit. She was also Executive Vice President of AstraZeneca and a member of its senior executive team.

Dr. Jallal is Chairman of the Board of Viela Bio, serves on the Board of Anthem, Inc. and is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation.

Dr. Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine. She is also the immediate past President of the Association of Women in Science. Dr. Jallal was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc.

Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in ParisVI. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

avatar_180x180_David Berman.jpg

Dr David Berman

Head of Research and Development

avatar_180x180_David Berman.jpg

Dr David Berman

Head of Research and Development

Over his career, David has worked on multiple immuno-oncology programs at all stages of development including leadership roles in developing four approved biologics. Most recently, David was Senior Vice President and Head of the AstraZeneca Immuno-oncology Franchise, responsible for the strategy and execution of the Company’s late stage IO programme.  Prior to that, he was Head of the early stage oncology programme at MedImmune. David has also held senior development roles at Bristol-Myers Squibb including Head of the Immuno-oncology exploratory development team and global clinical lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma. Beginning in academia and throughout his industry career, David has led efforts to understand the mechanism of action and predict benefit from IO therapies.

David received a bachelors of science from the Massachusetts Institute of Technology and MD and PhD from the University of Texas Southwestern Medical School.  He trained in pathology at the National Cancer Institute followed by a fellowship at the Johns Hopkins Hospital.

avatar_180x180_bent_jakobsen.jpg

Dr Bent Jakobsen

Chief Scientific Officer

avatar_180x180_bent_jakobsen.jpg

Dr Bent Jakobsen

Chief Scientific Officer

Bent co-founded Immunocore in 2008 and has served as Chief Scientific Officer and Executive Board Member since that time. He is also scientific co-founder of Adaptimmune Ltd, where he provides strategic and advisory input as well as oversight of research programmes. He was previously Chief Scientific Officer of Avidex, a company he founded in 1999 as a spin-out from the University of Oxford to develop novel T cell receptor-based drugs. Bent was head of the Immune Receptor Group at the Institute of Molecular Medicine (IMM) in Oxford from 1993 to July 2000. Prior to this, he was a Senior Research Fellow of the Danish Natural Research Council, Aarhus, Denmark, and undertook post-doctoral research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge. Bent has authored numerous scientific papers and is considered a world expert in the field of T cell receptor immunology. In 2015, he was recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.

avatar_180x180_andrew_hotchkiss.jpg

Andrew Hotchkiss

Chief Commercial Officer

avatar_180x180_andrew_hotchkiss.jpg

Andrew Hotchkiss

Chief Commercial Officer

Andrew joined Immunocore as Chief Commercial Officer in October 2017. He has more than 30 years’ experience in the pharmaceutical sector and has held numerous cross-functional roles spanning sales, marketing, corporate strategy, commercial strategy, country management, business development and regional leadership. Andrew joined Immunocore from Eli Lilly & Co, where he served in a number of global leadership positions across multiple therapeutic areas and geographies including as Vice President International Business Unit Leader Oncology, President Biomedicines Business Unit, Australia, Canada and Europe and Snr VP Digital Ventures.

Andrew has also served as Chairman of the European Markets Committee at EFPIA. He received his degree in Biochemistry from Cardiff University.

avatar_180x180_dr_mohammed_dar.jpg

Mohammed Dar

Head of Clinical Development and Chief Medical Officer

avatar_180x180_dr_mohammed_dar.jpg

Mohammed Dar

Head of Clinical Development and Chief Medical Officer

Mohammed joined Immunocore in April 2019 as Head of Clinical Development and Chief Medical Officer.

Mohammed has over 15 years of pharmaceutical industry experience in the field of oncology. Before joining Immunocore, Mohammed was Vice President, Clinical Development Oncology, R&D at MedImmune (AstraZeneca) and spent 10 years at GSK in roles of increasing responsibility focused on early clinical development in oncology. While at MedImmune, he led the clinical trials and teams supporting the approval of anti-PD-L1 checkpoint inhibitor, durvalumab, and anti-CD22 immunotoxin, moxetumomab.

Mohammed received his Bachelor’s Degree in Chemistry from the University of North Carolina at Chapel Hill and his M.D. and Internal Medicine training from Duke University School of Medicine. He went on to complete his Fellowship in Hematology and Oncology at the National Cancer Institute.

Board of Directors

avatar_180x180_john_bell.jpg

Professor Sir John Bell

Non-Executive Chairman

avatar_180x180_john_bell.jpg

Professor Sir John Bell

Non-Executive Chairman

Professor Sir John Bell was appointed to the Immunocore Board in March 2015. Professor Bell is the Regius Professor of Medicine at Oxford University and Chairman of the Office for the Strategic Coordination of Health Research. He is regarded as one of the world’s most distinguished scientists in the fields of genomic and genetic research and immunology, also has significant experience in the Healthcare industry, having been a founding director at three biotechnology companies; Avidex Ltd (a precursor to Immunocore which was acquired by MediGene in 2006), Oxagen and PowderJect Pharmaceuticals plc (acquired by Chiron Corporation in 2003). He currently also serves on the boards of Roche and Genentech and had a previous role on the scientific advisory board at AstraZeneca. Professor Bell was involved in the founding of the Wellcome Trust Centre for Human Genetics at Oxford University, now chairs the scientific committee of UK Biobank and the Global Health Scientific Advisory Board of the Bill and Melinda Gates Foundation, and is one of three Life Science Champions for the UK, reporting to the UK Prime Minister. His research has contributed significantly to the understanding of immune activation in a number of auto-immune diseases.

avatar_180x180_kristine_peterson.jpg

Ms Kristine Peterson

Non-Executive

avatar_180x180_kristine_peterson.jpg

Ms Kristine Peterson

Non-Executive

Kristine Peterson was appointed to the Immunocore Board of Directors as a Non-Executive Director in January 2018. Ms Peterson has more than 30 years’ experience in the global pharmaceutical and biotech industry.  Her most recent role was as Chief Executive Officer for Valeritas, Inc., where she led the company’s development from early stage R&D through to commercialisation, achieving approval by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the company’s Type 2 diabetes drug-device. In addition, Kristine raised more than $200 million in equity financing and prepared the company for its public listing on NASDAQ. Prior to Valeritas, Kristine was Company Group Chair at Johnson & Johnson for their worldwide biotech and oncology groups, growing those businesses to more than $6 billion in sales, launching several new products, and re-establishing the foundation for oncology R&D. She was also President and Senior Vice President, Commercial Operations for Biovail Corporation with responsibility for the US and Canadian business units. Earlier in her career, Kristine spent 20 years at Bristol-Myers Squibb in a variety of senior roles, including running their cardiovascular and metabolics business unit.

Kristine continues to play a role on several other Boards of Directors at pharmaceutical and biotech companies including Amarin Corporation, Paratek Pharmaceuticals, Enanta Pharmaceutics, pSivida, and ImmunoGen. She is also a senior advisor to the Healthcare Businesswomen’s Association and a former Member of the Biotechnology Industry Organization Board.

avatar_180x180_nick_cross.jpg

Mr Nicholas Cross

Non-Executive

avatar_180x180_nick_cross.jpg

Mr Nicholas Cross

Non-Executive

Mr Nicholas Cross was a co-founder of Immunocore in 2008 and served as Chairman for the first five years. He was previously a significant investor in and non-executive director of Avidex from 2000 - 2006. Mr Cross is a serial entrepreneur and hands-on investor. His previous ventures have included Adaptimmune where he was a co-founder and Chairman for the first five years, Oxford Asymmetry Ltd (now part of Evotec), Oxford Semiconductor Ltd (now part of Toshiba) in both of which he was also a co-founder and first Chairman, Doctors.net (now part of M3 Corporation), Oxxon (now part of Oxford Biomedica), Lansdown Estates Group Ltd (now MEPC Milton Park Ltd.), and Oxagen Ltd. Mr Cross holds a BA degree from the University of Oxford and an MBA from London Business School.

avatar_180x180_jean_michel_cossery.jpg

Dr Jean-Michel Cosséry

Non-Executive

avatar_180x180_jean_michel_cossery.jpg

Dr Jean-Michel Cosséry

Non-Executive

Jean-Michel Cosséry, Ph.D is a senior Healthcare Executive with global leadership experience in research, marketing and commercial roles within med-tech and pharmaceuticals. Dr Cosséry spent 10 years at GE Healthcare as the Chief Marketing Officer and Vice-President Global Marketing. He represented GEHC at the GE Strategic Board level and he was a member of the board for the Wipro-GE Healthcare join venture in India.  More recently, Dr Cosséry was with Eli-Lilly acting as Vice-President, North American Oncology, as well as Managing Director Northern Europe (including the UK and Ireland). Externally, Dr Cosséry represented Lilly in the CEO Forum in Washington DC, was a board member of the ABPI and the Chairman of the Board of the American Pharmaceutical Group.

Dr Cosséry holds an MBA from the Rotterdam School of Management (Erasmus University), The Netherlands. He received his Ph.D with honours in Nuclear Chemistry and Neurobiology from University Paris, France, and conducted post-doctoral research in Neuropharmacology at the NIH in the United States. Additionally, he holds a Pharm D with honours in Pharmacology from the University of Paris.

avatar_180x180_abbas_hussain.jpg

Mr Abbas Hussain

Non-Executive

avatar_180x180_abbas_hussain.jpg

Mr Abbas Hussain

Non-Executive

Abbas Hussain was appointed to the Immunocore Board of Directors as a Non-Executive Director in May 2017. Mr Hussain was most recently President of Global Pharmaceuticals at GlaxoSmithKline (GSK) where he had overall responsibility for the company’s sales business and led operations supporting commercial infrastructure including medical, finance, Human Resources, IT, legal and communications. He chaired GSK’s Pharmaceutical Operations Committee, driving key decisions on commercial strategy, and was on the Board of ViiV Healthcare Ltd., GSK’s HIV-specialised business unit. Mr Hussain previously served as GSK’s President of Emerging Markets where he was responsible for building the world’s leading emerging markets pharmaceuticals business by volume, and for driving the implementation of a new commercial operating model across more than 100 countries, helping to improve the transparency of GSK’s work with healthcare professionals. Prior to joining GSK, Mr Hussain served in a number of roles at Eli Lilly & Company, ultimately as Head of European Operations. Born in Madras, India, Abbas has a degree in Medicinal Chemistry & Pharmacology from Loughborough University in the UK.

avatar_180x180_jonathan_knowles.jpg

Dr Jonathan Knowles

Non-Executive

avatar_180x180_jonathan_knowles.jpg

Dr Jonathan Knowles

Non-Executive

Dr Jonathan Knowles has been a Non-Executive Director of Immunocore since 2010 and became Executive Chairman in November 2013. He was formerly President of Group Research and a Member of the Executive Committee at F. Hoffman-LaRoche Ltd, Basel, Switzerland for 12 years. Dr Knowles also served as a Board Member at Genentech Inc. for over 10 years and was a Member of the Board of Chugai Pharmaceuticals, Tokyo, Japan. Prior to joining Roche in 1997, he was Research Director at Glaxo Wellcome Europe. Dr Knowles has also served as Chairman of the Hever Group and the EFPIA Research Directors Group. He was instrumental in creating the Innovative Medicines Initiative (IMI) and was the first Chairman of the Board of IMI (a Joint Undertaking with the EU Commission). He is a Distinguished Professor (FiDiPro) at the University of Helsinki, Finland, holds a visiting chair at the University of Oxford, and is a visiting scholar of Pembroke College, Cambridge. In 2017, Dr Knowles was recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.

avatar_180x180_ian_laing.jpg

Mr Ian Laing

Non-Executive

avatar_180x180_ian_laing.jpg

Mr Ian Laing

Non-Executive

Mr Ian Laing has served as a Non-Executive Director of Immunocore since 2008 and is a founder shareholder of the company. Having started his career in commercial property, Mr Laing has been an active investor in life science and technology businesses for 25 years. He was previously a founder shareholder and Non-Executive Director of Oxford Asymmetry International plc (subsequently Evotec) from 1992 to 2000, Doctors.net.uk, Oxagen and Oxford Semiconductor Ltd. He is currently a Non-Executive Director of several private companies including Aegate Ltd, Phosphonics Ltd and SQW Group Ltd. Mr Laing is a Trustee of the Nuffield Medical Trust and was formerly Deputy Chairman of London Business School and a Non-Executive Director of the Oxford Radcliffe Hospitals NHS Trust. He is a Governor of the Royal Shakespeare Company and a Barclay Fellow of Green Templeton College and an Honorary Fellow of St. Edmund Hall in the University of Oxford. Mr Laing holds a MA degree from the University of Oxford and an MBA from London Business School.

avatar_180x180_george_robinson.jpg

Mr George Robinson

Non-Executive

avatar_180x180_george_robinson.jpg

Mr George Robinson

Non-Executive

Mr George Robinson has served as a Non-Executive Director of Immunocore since 2008. Mr Robinson is a partner of Sloane Robinson LLP, an investment management business specialising in global equities which he co-founded in 1993. Prior to that, he worked in Asia for 15 years, initially for Cathay Pacific Airways in Hong Kong, Korea and the Philippines, and then for Asia-based stockbroker WI Carr in Korea, Thailand and Hong Kong where he was Director of Regional Research. Mr Robinson graduated with a BA in Engineering Science from Keble College, Oxford in 1979, and is an honorary fellow of Keble College, Oxford as well as a member of the Oxford University Endowment Investment Committee.

avatar_180x180_laura_wade_gery.jpg

Ms Laura Wade-Gery

Non-Executive

avatar_180x180_laura_wade_gery.jpg

Ms Laura Wade-Gery

Non-Executive

Laura Wade-Gery was appointed to the Immunocore Board of Directors as a Non-Executive Director in January 2018. Ms Wade-Gery has more than 20 years’ executive experience within major publicly-listed companies. She most recently served as an Executive Director at Marks & Spencer Group plc (M&S) as Executive Director of Multi-Channel, with responsibility for both stores and online. During her five years at M&S, she successfully doubled online sales through the development and implementation of digital technology to transform its traditional business. Prior to M&S, Laura served at Tesco plc in several senior positions, most notably for seven years as Chief Executive Officer of the group’s online business Tesco.com, taking it from early stage development to a profitable business of over £2 billion sales, making it the global leader in online grocery.

Laura has also served on the Board of Trinity Mirror plc. She currently serves as a Non-Executive Director on the Boards of the John Lewis Partnership and British Land plc and is a member of the Governments Digital Strategy Advisory Board.

avatar_180x180_Bahija_Jallal.jpg

Dr Bahija Jallal

Chief Executive Officer

avatar_180x180_Bahija_Jallal.jpg

Dr Bahija Jallal

Chief Executive Officer

Dr. Bahija Jallal is Chief Executive Officer and Director of the Board of Immunocore. Prior to joining Immunocore in January 2019, she was President of MedImmune, Astra Zeneca’s global biologics research and development unit. She was also Executive Vice President of AstraZeneca and a member of its senior executive team.

Dr. Jallal is Chairman of the Board of Viela Bio, serves on the Board of Anthem, Inc. and is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation.

Dr. Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a Council Member of the Government-University-Industry Research Roundtable of the National Academies of Sciences, Engineering and Medicine. She is also the immediate past President of the Association of Women in Science. Dr. Jallal was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association.

Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc.

Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in ParisVI. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.

avatar_180x180_bent_jakobsen.jpg

Dr Bent Jakobsen

Chief Scientific Officer

avatar_180x180_bent_jakobsen.jpg

Dr Bent Jakobsen

Chief Scientific Officer

Bent co-founded Immunocore in 2008 and has served as Chief Scientific Officer and Executive Board Member since that time. He is also scientific co-founder of Adaptimmune Ltd, where he provides strategic and advisory input as well as oversight of research programmes. He was previously Chief Scientific Officer of Avidex, a company he founded in 1999 as a spin-out from the University of Oxford to develop novel T cell receptor-based drugs. Bent was head of the Immune Receptor Group at the Institute of Molecular Medicine (IMM) in Oxford from 1993 to July 2000. Prior to this, he was a Senior Research Fellow of the Danish Natural Research Council, Aarhus, Denmark, and undertook post-doctoral research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge. Bent has authored numerous scientific papers and is considered a world expert in the field of T cell receptor immunology. In 2015, he was recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.

Our partners

In addition to a well-established pipeline of wholly-owned programmes, Immunocore’s transformational science and strong IP position has led to multi-target discovery partnerships with Genentech, GlaxoSmithKline and AstraZeneca, to develop new cancer therapies using the ImmTAC® technology platform. A fourth partnership, with Eli Lilly, includes a co-development option in addition to ImmTAC® molecule co-discovery.

Outside of oncology, the Bill and Melinda Gates Foundation announced investment of up to $40 million to support the expansion of Immunocore’s technology platform to develop ImmTAV®/ImmTAB® molecules for the treatment of infectious diseases.

AstraZeneca  GenentechGlaxo Smith Kline Lilly Bill and Melinda Gates Foundation

Our locations

Oxfordshire, UK

Oxfordshire, UK

Immunocore Limited
101 Park Drive
Milton Park
Abingdon
Oxon
OX14 4RY

View Google Map
Oxfordshire, UK

Oxfordshire, UK

Immunocore Limited
101 Park Drive
Milton Park
Abingdon
Oxon
OX14 4RY

View Google Map
Pennsylvania, USA

Pennsylvania, USA

Immunocore LLC
Six Tower Bridge, Suite 200
181 Washington Street
Conshohocken, PA
19428
US

View Google Map
Pennsylvania, USA

Pennsylvania, USA

Immunocore LLC
Six Tower Bridge, Suite 200
181 Washington Street
Conshohocken, PA
19428
US

View Google Map